Revolutionizing Atopic Dermatitis Recap: Day 2

Previewing Dermatology Times Editorial Advisory Board Member Sessions at RAD 2023

Among numerous sessions being held this weekend at the Revolutionizing Atopic Dermatitis Conference in Washington, DC, several Dermatology Times® Editorial Advisory Board members are preparing to share their knowledge and insights.

FFPE-Based Molecular Classifier Precisely Separates Eczema From Psoriasis

A recently presented poster session from RAD 2023 evaluated a gene expression based molecular test’s differential diagnosis of psoriasis and eczema.

Upadacitinib, Long-Term Control, and Tapinarof, Oh My!

Raj Chovatiya, MD, PhD, discusses highlights from his sessions at RAD 2023 on best practices for AD management.

Determining Systemic Therapy Eligibility in Patients With Atopic Dermatitis

Andrew Blauvelt, MD, MBA, shares highlights from his RAD session, "Battle of the Titans 2: Challenging Patient Cases: Who is Eligible for Systemic Treatment in Atopic Dermatitis?"

Using Biologic Treatments in Atopic Dermatitis

Andrew Blauvelt, MD, MBA, discusses his RAD 2023 session, "Biologics for atopic dermatitis."

Systemic Treatment, Immunosuppressants, and JAK Inhibitor Session Highlights

Jonathan Silverberg, MD, PhD, MPH, shares highlights and key takeaways from his RAD 2023 sessions.

Christopher Bunick, MD, PhD, Discusses Late-Breaking Long-Term 4-Year Safety of Upadacitinib for AD

Bunick discusses the most important highlights of his late-breaking session at RAD 2023.

Keep up to date with the latest in coverage from the conference and subscribe to Dermatology Times to receive daily email updates.